Volume 17, Issue 2, Pages (March 2014)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 15, Issue 8, Pages (December 2012)

Volume 18, Issue 4, Pages (June 2015)

Volume 18, Issue 5, Pages (July 2015)

Mapping the COPD Assessment Test onto EQ-5D

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results Becky Pennington, MSc,

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-

Volume 14, Issue 1, Pages (January 2011)

Volume 18, Issue 4, Pages (June 2015)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 14, Issue 4, Pages (June 2011)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 6, Pages (September 2012)

Volume 14, Issue 8, Pages (December 2011)

Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores

Volume 15, Issue 1, Pages (January 2012)

Volume 19, Issue 5, Pages (July 2016)

Volume 15, Issue 2, Pages (March 2012)

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 5, Pages (July 2011)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

Value in Health Regional Issues

Eric Nsiah-Boateng, MPH, Moses Aikins, PhD

Value in Health Regional Issues

The Development of the Romanian Scorecard HTA System

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Bloodstream Infection in the Intensive Care Unit: Preventable Adverse Events and Cost Savings Claudia Balbuena Dal Forno, MD, MSc, Luci Correa, MD, PhD,

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia Mihajlo Jakovljević, MD, PhD,

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Value in Health Regional Issues

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Children Hospitalized for Varicella: Complications and Cost Burden

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries Travor Mabugu,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Assessment of Health Care and Economic Costs Due to Episodes of Acute Pesticide Intoxication in Workers of Rural Areas of the Coquimbo Region, Chile

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 17, Issue 2, Pages 183-195 (March 2014) Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder Anne-Lise Vataire, MSc, Samuel Aballéa, MSc, Fernando Antonanzas, Pr, Leona Hakkaart-van Roijen, MD, Raymond W. Lam, MD, Paul McCrone, PhD, Ulf Persson, PhD, Mondher Toumi, PhD Value in Health Volume 17, Issue 2, Pages 183-195 (March 2014) DOI: 10.1016/j.jval.2013.11.012 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Example of treatment strategy (“medium treatment strategy”). AE, adverse event; LoE, lack of efficacy. Value in Health 2014 17, 183-195DOI: (10.1016/j.jval.2013.11.012) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Model structure. Value in Health 2014 17, 183-195DOI: (10.1016/j.jval.2013.11.012) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Distribution of average number of days and costs by year and clinical status. QALYs, quality-adjusted life-years. Value in Health 2014 17, 183-195DOI: (10.1016/j.jval.2013.11.012) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Distribution of costs by year and clinical status. Value in Health 2014 17, 183-195DOI: (10.1016/j.jval.2013.11.012) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Tornado charts for non–treatment-relative parameters. QALYs, quality-adjusted life-years. Each bar represents the variation of the difference in QALYs and societal costs when the input values are changed according to scenarios specified in the Table 1. The vertical line represents the base case. Assumptions are shown in bold font. Value in Health 2014 17, 183-195DOI: (10.1016/j.jval.2013.11.012) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions